The approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.

AstraZeneca secures EU approval for Imfinzi in muscle-invasive bladder cancer, expanding its cancer treatment portfolio.

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

Nine years after my bladder cancer diagnosis, I reflect on its recurrence, caregiving, grief, and my new life with leukemia ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

Bladder cancer may be scary but it will help to know that depending on the stage of cancer treatment will help control or ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Anktiva (nogapendekin alfa inbakicept) for adults with BCG-unresponsive non-muscle invasive bladder cancer, where ...

The FDA designates the TOBY Test as a breakthrough device, revolutionizing bladder cancer detection with a non-invasive, ...

British drugmaker AstraZeneca (LSE: AZN) has gained European approval for Imfinzi (durvalumab) in combination with ...

Joseph Jacob, MD, discusses the promising impact of TAR-200.

The Cambridge, England-based pharmaceutical company said Imfinzi has been approved in the EU for treatments in adults with resectable muscle-invasive bladder cancer. The approval is for the use of ...

Bladder Cancer is a disease where cancer cells form in the tissues of the bladder. More common in males than females over 55 ...